Peggy Scherle, Ph.D.


Chief Scientific Officer

Peggy Scherle, Ph.D. has served as Chief Scientific Officer at Prelude Therapeutics since 2018. Prior to joining Prelude, Dr. Scherle held several roles at Incyte Corporation, most recently serving as Group Vice President, Discovery Biology and Preclinical Pharmacology where she oversaw the target validation and preclinical drug discovery efforts. Her prior roles at Incyte included Vice President, Preclinical Pharmacology from 2014 until 2017 and as Executive Director, In Vitro Biology from 2011 until 2014. Dr. Scherle was one of the original team of scientists that joined Incyte in 2002 and was involved in the discovery and development of the JAK inhibitors, JakafiĀ® (ruxolitinib), for the treatment of myelofibrosis and polycythemia vera, and OlumiantĀ® (baricitinib), for rheumatoid arthritis, as well as the advancement of >10 small molecules into clinical studies for cancer, including both targeted therapy and immunotherapy approaches. Prior to Incyte, Dr. Scherle held scientific research positions with DuPont Pharmaceuticals Company and Bristol- Myers Squibb. Dr. Scherle received her Ph.D. in immunology from the University of Pennsylvania and completed her postdoctoral training at the NIH.